trending Market Intelligence /marketintelligence/en/news-insights/trending/Sl8jhJKQ3TpujY4vzPk4XA2 content esgSubNav
In This List

Neos Therapeutics settles patent case against Teva unit for ADHD drug

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022

Blog

Insight Weekly: CEO pay jumps; yield curve inversion deepens; wind giants lift turbine prices


Neos Therapeutics settles patent case against Teva unit for ADHD drug

Neos Therapeutics Inc. agreed to settle its patent infringement case filed against a unit of Teva Pharmaceutical Industries Ltd.

Neos filed a complaint in December 2017 with the U.S. District Court for the District of Delaware alleging that an abbreviated new drug application for the generic version of Cotempla XR-ODT, or methylphenidate, filed with the U.S. Food and Drug Administration by Teva unit Teva Pharmaceuticals USA Inc. infringed its patents.

Under the agreement, Neos has given Teva rights to manufacture and market the generic version of Cotempla XR-ODT starting in 2026 or earlier under certain circumstances.

Cotempla XR-ODT is approved by the FDA to treat attention deficit hyperactivity disorder in patients aged 6 to 17 years old.

Neos did not share any details of the agreement, which is subject to submission to the Federal Trade Commission and the U.S. Department of Justice.